Hours after Allergan (NYSE:AGN) said it was considering an acquisition of Shire (NSDQ:SHPG), the Dublin-based company announced that it does not intend to make such an offer.
Reports also surfaced today that Shire rejected a $63 billion takeover offer from Takeda Pharmaceutical (TYO:4502).
Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, also broke the news that Shire rejected Takeda’s third, $66-per-share offer earlier today, which the Japanese company later confirmed.
Takeda’s most recent, £46.50-per-share bid (about $66.00) was comprised of £17.75 ($25.20) in cash to be paid in U.S. dollars and £28.75 ($40.80) worth of new Takeda shares; Shire estimated that the offer put its value at £44 billion ($62.44 billion).
The Japanese company’s first offers were for £44 ($62.44) and £45.50 ($64.57) per share, respectively. Its deadline under U.K. law falls on April 25.
($1 = £0.704501)
Updated on 4/19 to include Allergan’s latest statement.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.